A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
600
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer Disease
Agitation
Interventions
DRUG:
KarXT
DRUG:
KarX-EC
Sponsor
Bristol-Myers Squibb